Eli Lilly drug preserves lean mass in patients losing weight on Wegovy

Taking stock of the drug industry, from the lab to the medicine chest

June 23, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jose Luis Magana/AP STAT+ | Top drug regulator is retiring as FDA departures mount Jacqueline Corrigan-Curay, who runs a key FDA center, is the latest top official to depart the agency. By Lizzy Lawrence STAT+ | Compass psilocybin therapy shown to be effective in largest-ever study in depression Single dose of psychedelic drug led to a mean reduction of 3.6 points on standard measure of clinical depression with no safety issues raised By Olivia Goldhill STAT+ | Amgen's obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing The results that the company's decision to use a slower dosing schedule to make the drug more tolerable in further testing. By Elaine Chen Adobe STAT+ | Eli Lilly drug preserves lean mass in patients losing weight on Wegovy In a Phase 2 trial, patients taking a combination of Wegovy and bimagruamb lost 22% of their weight, compared with 16% on Wegovy alone. By Elaine Chen STAT+ | GLP-1 drug helped type 1 diabetes patients keep healthy glucose levels and lose weight Now used for type 2 diabetes, new study shows GLP-1 drugs helped people with type 1 keep blood glucose levels in a healthy range while also losing weight. By Elizabeth Cooney STAT+ | Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs Novo alleges that Hims has been engaging in "illegal mass compounding" of GLP-1 obesity treatments and "deceptive marketing." By Elaine Chen LISELOTTE SABROE/Scanpix/AFP via Getty Images STAT+ | Novo Nordisk's amylin obesity drug keeps performing like Zepbound Late-stage results of Novo Nordisk's CagriSema suggest the weight loss drug may not be the standout treatment that investors had hoped for. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser